Wake Forest University, Department of Urology, Winston-Salem, NC, USA.
Wake Forest University, Department of Urology, Winston-Salem, NC, USA.
Eur Urol. 2014 Jun;65(6):1162-8. doi: 10.1016/j.eururo.2013.11.017. Epub 2013 Nov 21.
Pilot studies have demonstrated the utility of indocyanine green (ICG) sentinel lymphadenectomy for prostate cancer. Prior work has used ICG with radiocontrast agents injected at a separate procedure and relied on assistant-controlled fluorescence systems, making the technique costly and cumbersome.
To describe the initial optimization and feasibility of fluorescence-enhanced robotic radical prostatectomy (FERRP) using real-time injection of ICG for tissue marking and identification of sentinel lymphatic drainage visualized by a fully integrated surgeon-controlled system.
DESIGN, SETTING, AND PARTICIPANTS: Patients with clinically localized prostate cancer at a tertiary referral center were offered FERRP. Ten patients participated in a pilot arm in which ICG dosing and injection technique were optimized. Fifty consecutive patients then underwent FERRP.
After development of the space of Retzius, 0.4 ml of a 2.5 mg/ml ICG solution were injected into each lobe of the prostate using a robotically guided percutaneous needle. After ICG was allowed to travel through the pelvic lymphatics, lymphadenectomy was performed from the endopelvic fascia to the aortic bifurcation.
Parameters describing the time course of tissue fluorescence and pelvic lymphangiography were systematically recorded. Lymphatic packets containing fluorescent nodes were considered sentinel.
Percutaneous, robotic-guided ICG injection proved superior to cystoscope or transrectal delivery. Tissue marking was achieved in all patients, positively identifying the prostate with uniform fluorescence relative to the obturator nerve, seminal vesicles, vas deferens, and neurovascular pedicles at a mean time of 10 min postinjection. Sentinel nodes were identified in 76% of patients at a mean time of 30 min postinjection and had 100% sensitivity, 75.4% specificity, 14.6% positive predictive value, and 100% negative predictive value for the detection of nodal metastasis.
FERRP is safe, feasible, and allows for reliable prostate tissue marking and identification of sentinel lymphatic drainage in the majority of patients. ICG sentinel nodes are highly sensitive but relatively nonspecific for the detection of nodal metastasis.
初步研究表明,吲哚菁绿(ICG)前哨淋巴结切除术可用于前列腺癌。先前的研究使用放射性对比剂在单独的程序中注射 ICG,并依赖于辅助控制的荧光系统,使得该技术昂贵且繁琐。
描述使用实时注射 ICG 进行组织标记以及通过完全集成的外科医生控制的系统可视化前哨淋巴结引流的荧光增强机器人根治性前列腺切除术(FERRP)的初始优化和可行性。
设计、地点和参与者:在三级转诊中心,患有临床局限性前列腺癌的患者被提供 FERRP。10 名患者参加了优化 ICG 剂量和注射技术的试验臂。然后,50 名连续患者接受了 FERRP。
在开发 Retzius 间隙后,使用机器人引导的经皮针将 0.4ml 2.5mg/ml 的 ICG 溶液注射到前列腺的每个叶中。在 ICG 允许通过盆腔淋巴管行进后,从盆内筋膜到主动脉分叉进行淋巴结切除术。
系统地记录描述组织荧光和盆腔淋巴管造影时间过程的参数。含有荧光节点的淋巴包被认为是前哨。
经皮机器人引导的 ICG 注射优于膀胱镜或经直肠递送。在所有患者中均实现了组织标记,与闭孔神经、精囊、输精管和神经血管蒂相比,前列腺在注射后 10 分钟内具有均匀的荧光,从而可以准确定位前列腺。在注射后 30 分钟内,76%的患者识别出前哨淋巴结,其检测淋巴结转移的灵敏度为 100%,特异性为 75.4%,阳性预测值为 14.6%,阴性预测值为 100%。
FERRP 是安全、可行的,可在大多数患者中可靠地进行前列腺组织标记和识别前哨淋巴结引流。ICG 前哨淋巴结对检测淋巴结转移具有高度敏感性,但特异性相对较低。